BiotechTube

emtricitabine/tenofovir disoproxil fumarate

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Human Immunodeficiency Virus

Conditions

Human Immunodeficiency Virus

Trial Timeline

Feb 1, 2011 → May 1, 2013

NCT ID
NCT01234116

About emtricitabine/tenofovir disoproxil fumarate

emtricitabine/tenofovir disoproxil fumarate is a approved stage product being developed by Merck for Human Immunodeficiency Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT01234116. Target conditions include Human Immunodeficiency Virus.

What happened to similar drugs?

13 of 20 similar drugs in Human Immunodeficiency Virus were approved

Approved (13) Terminated (4) Active (7)
✅lopinavir/ritonavirAbbVieApproved
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
✅3-drug anti-HIV therapy + RaltegravirMerckApproved
✅GardasilMerckApproved
✅RaltegravirMerckApproved
✅RaltegravirMerckApproved
✅EBR/GZRMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01234116ApprovedCompleted

Competing Products

20 competing products in Human Immunodeficiency Virus

See all competitors
ProductCompanyStageHype Score
Influenza vaccine, split inactivatedComac MedicalPhase 1
19
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
40
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
35
DolutegravirShionogiPhase 3
40
GSK1349572 + efavirenzShionogiPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
29
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
40
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
29
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
29
dolutegravirShionogiPhase 3
40
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
40
GSK1349572 + EfavirenzShionogiPhase 1
29
GSK1349572ShionogiPhase 1
29
GSK1349572 + PlaceboShionogiPhase 2
35
Dolutegravir + MethadoneShionogiPhase 1
29
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir PlaceboShionogiPhase 3
40
GSK1349572 + Rifampin + RifabutinShionogiPhase 1
29
DTG + BCV + TVRShionogiPhase 1
29